Beneficial effect of switching from a combination of angiotensin II receptor blockers other than losartan and thiazides to a fixed dose of losartan/hydrochlorothiazide on uric acid metabolism in hypertensive patients

Clinical and Experimental Hypertension

Volumn 33, Issue 8, 2011, Pages 565-570

  Ohshiro, Katsuhiko ^a   Sakima, Atsushi ^a   Nakada, Seigo ^b   Kohagura, Kentaro ^a   Yamazato, Masanobu ^a   Tana, Takeshi ^c   Ohya, Yusuke ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b Keiaikai Chibana Clinic   (Japan)

^c Shuri Jokamachi Clinic   (Japan)

Author keywords

diuretics; hypertension; losartan; uric acid; urine pH

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; INDAPAMIDE; LIPID; OLMESARTAN; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRICHLORMETHIAZIDE; URIC ACID; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERURICEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; URINARY EXCRETION; URINE LEVEL; URINE PH;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYDROCHLOROTHIAZIDE; HYDROGEN-ION CONCENTRATION; HYPERTENSION; HYPERURICEMIA; LOSARTAN; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS; TREATMENT OUTCOME; URIC ACID;

EID: 82455198881     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2011.577487     Document Type: Article

References (26)

1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289:2560-2572. (Pubitemid 37430158)
2. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751-1762. (Pubitemid 47356612)
3. Ogihara T, Kikuchi K, Matsuoka H, et al. Japanese Society of Hypertension Committee. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32:3-107.
4. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365:217-223. (Pubitemid 40138015)
5. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43:10-17. (Pubitemid 38031904)
6. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomized trials. BMJ 2003; 326:1427-1434.
7. Franse LV, PahorM, Di BariM, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18:1149-1154.
8. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34:144-150. (Pubitemid 29325733)
9. Høieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65:1041-1049. (Pubitemid 38251080)
10. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359:1811-1821.
11. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 23:447-452. (Pubitemid 34563537)
12. Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 2007; 320:211-217. (Pubitemid 46025736)
13. Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008; 21:1157-1162.
14. Shahinfar S, Simpson RL, Carides AD, et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999; 56:1879-1885. (Pubitemid 29518189)
15. Sakima A, Ohshiro K, Nakada S, et al. Switching therapy from variable-dose multiple pill to fixed-dose single-pill combinations of angiotensin II receptor blockers and thiazides for hypertension. Clin Exp Hypertens 2011; 33:309-315.
16. Maesaka JK, Fishbane S. Regulation of renal urate excretion: A critical review. Am J Kidney Dis 1998; 32:917-933. (Pubitemid 28551154)
17. Matsuo S, Imai E, HorioM, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53:982-992.
18. Kita T, Yokota N, Ichiki Y, et al. One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors. Hypertens Res 2010; 33: 320-325.
19. Naritomi K, Fujita T, Ito S, et al. Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study. Hypertens Res 2008; 31:295-304. (Pubitemid 351461110)
20. Bakris GL, Toto RD, McCullough PA, et al. Effects of different ACE inhibitor combinations on albuminuria: Results of the GUARD study. Kidney Int 2008; 73:1303-1309. (Pubitemid 351693145)
21. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in highrisk patients. N Engl J Med 2008; 359:2417-2428.
22. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: Evidence supporting their interchangeability. Hypertension 2004; 43:4-9. (Pubitemid 38031903)
23. Giacomello A, Di Sciascio N, Quaratino CP. Relation between serum triglyceride level, serum urate concentration, and fractional urate excretion. Metabolism 1997; 46:1085-1089. (Pubitemid 27371829)
24. Lin JL, Tan DT, Ho HH, Yu CC. Environmental lead exposure and urate excretion in the general population. Am J Med 2002; 113:563-568.
25. Uetake D, Ohno I, Ichida K, et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med 2010; 49: 89-94.
26. Hamada T, Hisatome I, Kinugasa Y, et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002; 41:793-797. (Pubitemid 35314777)